Anchor, Kyowa Hakko Kirin collaborate on pepducin tech for GPCR targets

Wednesday, August 1, 2012 11:15 AM

Anchor Therapeutics, a developer of pepducin technology, has entered into a collaborative agreement with Kyowa Hakko Kirin (KHK), a Japanese biopharmaceutical company, to advance KHK’s internal G protein-coupled receptor (GPCR) drug discovery portfolio.

The agreement takes advantage of Anchor’s expanded business strategy to offer its pepducin technology for use as in vitro and in vivo research tools, in addition to developing pepducin therapeutics.

Anchor and KHK will work jointly to discover and optimize pepducin research tools to further the molecular understanding of certain GPCR targets in the KHK portfolio. KHK will assume responsibility for application of the research tools against the targets. Anchor will receive an upfront payment, research funding, and downstream milestones.

“We are excited about this initial application of the pepducin technology as research tools and believe that this agreement will provide KHK with a unique perspective to better evaluate their GPCR targets and advance their internal drug discovery efforts,” said Thomas J. McMurry, interim president and senior vice president, R&D, Anchor Therapeutics. “The licensing of pepducin technology as a research tool is a fundamental component of our business strategy, and we are actively pursuing other collaborations with pharmaceutical and biotechnology companies and research institutions.”

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs